|
Recommendations
for primary prevention of AF with
‘upstream’ therapy |
|
|
|
Recommendations |
Evidencia |
ACEIs and ARBs should be
considered for prevention of newonset
AF in patients with heart
failure and reduced ejection fraction. |
IIa A |
ACEIs and ARBs should be considered
for prevention of new-onset
AF in patients with hypertension,
particularly with left ventricular
hypertrophy. |
IIa B |
Statins should be considered for
prevention of new-onset AF after
coronary artery bypass grafting,
isolated or in combination with
valvular interventions |
IIa B |
Statins may be considered for prevention
of new-onset AF in patients
with underlying heart disease,
particularly heart failure.
|
IIb B |
Upstream therapies with ACEIs,
ARBs, and statins are not recommended
for primary prevention of
AF in patients without cardiovascular
disease.
|
III C |
ACEI: angiotensin-converting enzyme inhibitor; AF:atrial
fibrillation; ARB:
angiotensin receptor blocker. |
|
 |